LMR Partners’s Adverum Biotechnologies ADVM Stock Holding History

LMR Partners’s Portfolio ADVM Stock Details ADVM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-3,099	Closed	-$29K	–	1094
2022 Q3	$29K	Hold	3,099	–	–	﹤0.01%	1139
2022 Q2	$37K	Buy	+3,099	New	+$32.5K	﹤0.01%	1186
2017 Q3	–	Sell	-9,778	Closed	-$244K	–	312
2017 Q2	$244K	Buy	+9,778	New	+$267K	0.02%	502

Other funds holding ADVM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

SGL

Sonic GP LLC Honolulu, Hawaii $45.4M AUM 5.08% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

LMR Partners's ADVM Position: Q4 2022 in Review

LMR Partners sold out of Adverum Biotechnologies (ADVM) in Q4 2022, closing a stake of 3,099 shares — an estimated $29K sold.

LMR Partners first reported a position in ADVM in Q2 2017 and held it in 3 quarters. The position peaked at $244K in Q2 2017. 59 funds tracked by Wall St. Rank hold ADVM as of Q4 2022.

LMR Partners reported no remaining Adverum Biotechnologies position as of Q4 2022 after selling out during the quarter.
LMR Partners sold 3,099 Adverum Biotechnologies shares in Q4 2022, an estimated $29K.
LMR Partners first reported a position in Adverum Biotechnologies in Q2 2017 and held it in 3 quarters.
LMR Partners's Adverum Biotechnologies position peaked at $244K in Q2 2017.
59 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q4 2022.

Based on LMR Partners's 13F filing for Q4 2022, filed 14 Feb 2023.